| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Nitric oxide (NO) signaling pathways. Nitric oxide is a critical signaling molecule involved in the regulation of vascular tone, neurotransmission, immune function, and many other physiological processes. DETA NONOate is an exogenous NO donor that releases NO in a sustained and controlled manner. With a NO release half-life of 20 hours, DETA NONOate provides long-lasting NO exposure, allowing researchers to study the chronic effects of NO on cellular and physiological processes.
|
|---|---|
| ln Vitro |
By decreasing M's glycopeptide lipid (GPL) expression, DETA NONOate (100 μM; 16 h) stimulates the growth of the R form of the Mycobacterium abscessus complex (MABC). subspecies abscessus (Mab) of abscessus [3].
In vitro, DETA NONOate is an exogenous NO donor that activates inward currents in cultured rat cerebellar granule cells and increases cGMP production in vascular smooth muscle cells. The compound displays sustained release and long-lasting effects of normal amounts of NO. In cell-based assays, DETA NONOate induces cGMP accumulation, vasodilation, and other NO-mediated responses in a dose-dependent manner. The compound is widely used as a tool to study the effects of sustained NO exposure on various cell types and signaling pathways. |
| ln Vivo |
In the rat formalin model, DETA NONOate (15-150 μg/rat, intracerebroventricular injection, once) shows nociceptor effects[2]. DETA NONOate (1µM) inhibits apoptotic cell death and lessens cardiac mitochondrial damage caused by ischemia or ischemia/reperfusion[4].
In vivo, DETA NONOate is used as an NO donor to study the physiological and pathological roles of NO. By providing sustained NO release, the compound can be used to investigate the long-term effects of NO on vascular function, blood pressure, inflammation, and other processes. However, detailed in vivo efficacy data in specific disease models are limited in the available literature. |
| Enzyme Assay |
The in vitro NO release assay for DETA NONOate involves measuring the release of NO from the compound over time. DETA NONOate is incubated in buffer at physiological pH and temperature, and the accumulation of NO or its breakdown products (nitrite/nitrate) is measured using the Griess reagent or a chemiluminescence NO analyzer. The NO release kinetics, including the half-life, are determined from the time course of NO accumulation.
|
| Cell Assay |
In vitro cellular assays for DETA NONOate are performed using various cell types that respond to NO. Cells are treated with varying concentrations of DETA NONOate, and NO-mediated responses are measured. cGMP production is measured by ELISA or radioimmunoassay. Activation of inward currents can be assessed by patch-clamp electrophysiology in neuronal cells. Vasodilation can be assessed in isolated blood vessel preparations. The cellular responses to DETA NONOate are compared to those of other NO donors to evaluate the effects of sustained NO exposure.
|
| Animal Protocol |
Animal/Disease Models: SD (Sprague-Dawley) rats (Sixty-two, male, 200-250 g)[2]
Doses: 15 or 150 μg per rat Route of Administration: icv, once Experimental Results: Accelerated the nociception in a dose-dependent manner, and this acceleration was completely abolished by Methylene Blue. In vivo animal experiments for DETA NONOate are conducted in various animal models to study the effects of NO. The compound is administered via intravenous, intraperitoneal, or subcutaneous injection at various dose levels. Blood pressure, heart rate, and other cardiovascular parameters are monitored. NO-mediated effects on inflammation, neurotransmission, and other processes can be assessed by measuring appropriate biomarkers and functional endpoints. |
| ADME/Pharmacokinetics |
DETA NONOate is an exogenous NO donor that releases NO with a half-life of 20 hours. The compound is soluble in water at 50 mg/mL at 25°C and is typically supplied as a crystalline solid with a purity of ≥95%. The sustained release of NO from DETA NONOate allows for long-lasting effects on cellular and physiological processes.
|
| Toxicity/Toxicokinetics |
In preclinical studies, DETA NONOate is generally well-tolerated at doses that achieve NO-mediated effects. As an NO donor, the compound may cause vasodilation and hypotension at high doses due to the systemic effects of NO. Careful dose titration is required to avoid excessive NO-mediated effects. The compound is used for research purposes only and is not approved for human use.
|
| References |
|
| Additional Infomation |
1,1-Bis(2-aminoethyl)-2-hydroxy-3-oxotriazine is a nitroso compound with the structure triazine, wherein the nitrogen atom at position 1 is replaced by two 2-aminoethyl groups, the nitrogen atom at position 2 is replaced by a hydroxyl group, and the nitrogen atom at position 3 is replaced by an oxo group. It can act as a nitric oxide donor. It is a tertiary amine and nitroso compound derived from the hydride of triazine.
DETA NONOate (Diethylamine NONOate; NOC-18) is an exogenous nitric oxide (NO) donor. It has a CAS number of 146724-94-9, a molecular formula of C4H13N5O2, and a molecular weight of 163.18. DETA NONOate displays sustained release and long-lasting effects with an NO release half-life of 20 hours. DETA NONOate is not approved for human use and is intended for research purposes only. |
| Molecular Formula |
C4H13N5O2
|
|---|---|
| Molecular Weight |
163.18
|
| Exact Mass |
163.106
|
| CAS # |
146724-94-9
|
| PubChem CID |
135402056
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
303.0±52.0 °C at 760 mmHg
|
| Melting Point |
98-106ºC
|
| Flash Point |
137.1±30.7 °C
|
| Vapour Pressure |
0.0±1.4 mmHg at 25°C
|
| Index of Refraction |
1.588
|
| LogP |
-1.65
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
11
|
| Complexity |
122
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(CN(CCN)/[N+](=N/O)/[O-])N
|
| InChi Key |
YNRCBOXEDICOIX-CLFYSBASSA-N
|
| InChi Code |
InChI=1S/C4H13N5O2/c5-1-3-8(4-2-6)9(11)7-10/h10H,1-6H2/b9-7-
|
| Chemical Name |
(Z)-[bis(2-aminoethyl)amino]-hydroxyimino-oxidoazanium
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O: 50 mg/mL (306.41 mM)
DMSO: < 1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.1282 mL | 30.6410 mL | 61.2820 mL | |
| 5 mM | 1.2256 mL | 6.1282 mL | 12.2564 mL | |
| 10 mM | 0.6128 mL | 3.0641 mL | 6.1282 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA